A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
← catalyst calendarNCT05452941 · readout in 288 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
12,500estimated
Sites
54
Countries
Israel, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-27 | actual | When the study began enrolling |
| Primary completion | 2027-06-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-04 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pneumonia
Intervention
- Diagnostic test: Diagnostic test on urine samples
Primary outcome
what the primary-completion date above is the date OFEffectiveness of 20vPnC against all (invasive + non-invasive) RAD+CAP due to the 7 additional serotypes in 20vPnC beyond 13vPnC plus 15C
measured 55 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed